Literature DB >> 2635537

Serovirological study of vestibular neuronitis.

T Hirata1, T Sekitani, Y Okinaka, Y Matsuda.   

Abstract

A serovirological study to clarify the pathogenesis of vestibular neuronitis was made on 44 patients. The diagnosis of vestibular neuronitis was made under the diagnostic criteria. Sera from all 44 cases were collected twice or more at defined intervals. Of these, 36 cases were treated as paired sera. Seventeen out of 36 paired cases showed significant change in serum viral antibody titer (HSV, 2 cases; CMV, 1 case; EBV, 7 cases; rubella, 2 cases; adeno., 2 cases; influ. A, 1 case; influ. B, 2 cases). It was assumed that infection caused by these detected viruses played an important role in the onset of vertigo in each case.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2635537     DOI: 10.3109/00016488909139079

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  5 in total

1.  Expanding the spectrum of neurological disease associated with Epstein-Barr virus activity.

Authors:  M Kleines; J Schiefer; A Stienen; M Blaum; K Ritter; M Häusler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-15       Impact factor: 3.267

Review 2.  Vestibular neuronitis: a review of a common cause of vertigo in general practice.

Authors:  C W Cooper
Journal:  Br J Gen Pract       Date:  1993-04       Impact factor: 5.386

3.  Neuro-otological Symptoms: An Atypical Aspect of COVID-19 Disease.

Authors:  Faizah Ashfah Latief Deva; Anchal Gupta; Monica Manhas; Parmod Kalsotra
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2022-04-15

4.  New Onset Vertigo After COVID-19 Infection. A Case Report.

Authors:  Karam R Motawea; Fatma A Monib
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2021-07-04

Review 5.  Is vestibular neuritis an immune related vestibular neuropathy inducing vertigo?

Authors:  A Greco; G F Macri; A Gallo; M Fusconi; A De Virgilio; G Pagliuca; C Marinelli; M de Vincentiis
Journal:  J Immunol Res       Date:  2014-01-15       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.